Novel, Next-Generation HIV-1 Maturation Inhibitor GSK3640254 Demonstrates Dose-Dependent Antiviral Response in Treatment-Naive Patients With HIV Infection

March 6-10, 2021; Virtual
Phase IIa study demonstrates that novel maturation inhibitor exhibits dose-response antiviral activity, in vivo concentrations above clinical efficacy targets, and good tolerability.
Format: Microsoft PowerPoint (.ppt)
File Size: 223 KB
Released: March 10, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Download CCO slides reviewing data and guidelines on next-line ART for heavily-treatment experienced patients with HIV and multiclass drug resistance

Joseph J. Eron, Jr., MD Monica Gandhi, MD, MPH Released: April 19, 2021

Download CCO slides reviewing clinically relevant new data reported at CROI 2021 on a wide range of ART management topics.

Joseph J. Eron, Jr., MD Princy N. Kumar, MD, FIDSA, MACP Daniel R. Kuritzkes, MD Released: April 9, 2021

由专家选择的 2021 年 CROI 中的重要 HIV 数据,包括当前和研究性的 ART 疗法以及孕期和产后的 ART 疗法。数据由 CCO 提供

Princy N. Kumar, MD, FIDSA, MACP Daniel R. Kuritzkes, MD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Released: April 9, 2021

Seleção por peritos de dados importantes sobre o VIH da CROI 2021, incluindo o ART atual e de investigação e o ART na gravidez e no período pós-parto, da CCO

Princy N. Kumar, MD, FIDSA, MACP Daniel R. Kuritzkes, MD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Released: April 9, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue